Please assess the completion status of the following clinical trial:

Trial Title: Better Evidence for Selecting Transplant Fluids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult or child with End-Stage Kidney Disease, of any cause, on maintenance dialysis, or who has pre-dialysis stage 5 chronic kidney disease with an estimated Glomerular Filtration Rate of \<15 mL/min/1.73m2, AND~2. Planned deceased donor kidney transplant from a brain-death (DBD) or circulatory-death (DCD) organ donor within 24 hours, AND~3. Written informed consent, or consent given by their parent or guardian (if age \<18), or other authorised person~Exclusion Criteria:~1. Planned live donor kidney transplant (except where this is cancelled in favour or transplantation from a deceased donor)~2. Planned multi-organ transplant (dual or en-bloc kidney transplants are not excluded)~3. Children of weight \<20 kg, or a child that the treating physician believes should not be included in a study of blinded fluids due to their small body size~4. Known hypersensitivity to the trial fluid preparations or packaging

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Plasma-Lyte 148 (approx. pH 7.4) IV Infusion (Type: EXPERIMENTAL): Plasma-Lyte 148 (approx. pH 7.4) IV Infusion intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.
- 0.9% SODIUM CHLORIDE 9g/L injection BP (Type: ACTIVE_COMPARATOR): 0.9% saline intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.

Based on this trial design, predict the completion outcome and termination type (if applicable).